NCT03992131 - A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

March 8, 2022

Study Completion Date

April 22, 2022

Conditions

Ovarian CancerTriple-negative Breast CancerUrothelial CarcinomaSolid Tumor

Interventions

DRUG

Rucaparib

Rucaparib will be administered per schedule specified in the arm description.

DRUG

Lucitanib

Lucitanib will be administered per schedule specified in the arm description.

DRUG

Sacituzumab govitecan

Sacituzumab govitecan will be administered per schedule specified in the arm description.

Trial Locations (3)

Sarah Cannon Research Institute, Nashville

MD Anderson Cancer Center, Houston

Dana Farber Cancer Institute, Boston